ZA981838B - Functional DNA clone for hepatitis C virus (HCV) and uses thereof - Google Patents

Functional DNA clone for hepatitis C virus (HCV) and uses thereof

Info

Publication number
ZA981838B
ZA981838B ZA981838A ZA981838A ZA981838B ZA 981838 B ZA981838 B ZA 981838B ZA 981838 A ZA981838 A ZA 981838A ZA 981838 A ZA981838 A ZA 981838A ZA 981838 B ZA981838 B ZA 981838B
Authority
ZA
South Africa
Prior art keywords
hcv
hepatitis
virus
dna clone
functional dna
Prior art date
Application number
ZA981838A
Other languages
English (en)
Inventor
Charles M Rice Iii
Alexander A Kolykhalov
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of ZA981838B publication Critical patent/ZA981838B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA981838A 1997-03-04 1998-03-04 Functional DNA clone for hepatitis C virus (HCV) and uses thereof ZA981838B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/811,566 US6127116A (en) 1995-08-29 1997-03-04 Functional DNA clone for hepatitis C virus (HCV) and uses thereof

Publications (1)

Publication Number Publication Date
ZA981838B true ZA981838B (en) 1999-02-19

Family

ID=25206905

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA981838A ZA981838B (en) 1997-03-04 1998-03-04 Functional DNA clone for hepatitis C virus (HCV) and uses thereof

Country Status (9)

Country Link
US (4) US6127116A (enExample)
EP (1) EP1005366A4 (enExample)
JP (2) JP4094679B2 (enExample)
AU (1) AU742175B2 (enExample)
BR (1) BR9808147A (enExample)
CA (1) CA2283464C (enExample)
IL (2) IL131688A0 (enExample)
WO (1) WO1998039031A1 (enExample)
ZA (1) ZA981838B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
ES2306670T3 (es) * 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
DE19953854C2 (de) * 1999-11-09 2002-01-17 Max Planck Gesellschaft Verfahren zur Herstellung von Biopolymeren mit veränderten Eigenschaften
WO2001036442A1 (en) * 1999-11-17 2001-05-25 Jiuping Ji Simultaneous detection of hbv, hcv and hiv in plasma samples using a multiplex capture assay
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
US20010055756A1 (en) * 2000-04-21 2001-12-27 Charles Pellerin Internal de novo initiation sites of the HCV NS5B polymerase and use thereof
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6447994B1 (en) * 2000-06-20 2002-09-10 The General Hospital Corporation Production of replicative hepatitis C virus
US20040101827A1 (en) * 2000-10-03 2004-05-27 Michinori Kohara Methods of infection with hepatitis c virus
US20040005549A1 (en) * 2000-11-07 2004-01-08 Anadys Pharmaceuticals, Inc. Hepatitis C virus constructs characterized by high efficiency replication
AU2002225895A1 (en) * 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
NZ527035A (en) 2000-12-22 2006-02-24 Boehringer Ingelheim Ca Ltd Self-replicating RNA molecule from hepatitis C virus
CA2441688C (en) * 2001-03-27 2014-01-21 Vertex Pharmaceuticals Incorporated Compositions and methods useful for hcv infection
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
US20030152942A1 (en) * 2001-05-09 2003-08-14 Lance Fors Nucleic acid detection in pooled samples
US7871814B2 (en) * 2001-05-10 2011-01-18 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
WO2003040356A1 (en) * 2001-08-06 2003-05-15 Yangling Daiying Biological Engineering Co., Ltd The intact hepatitis c virus and the method for culturing it in a vitro cell culture
CA2461380C (en) * 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
US6689559B2 (en) * 2001-11-29 2004-02-10 The Research Foundation Of The State University Of New York Efficient hepatitis C virus replicon and its use in identifying antiviral compounds
ES2386742T3 (es) * 2002-03-11 2012-08-28 Lab 21 Limited Método y composiciones para identificar y caracterizar la Hepatitis C
KR100471946B1 (ko) * 2002-05-08 2005-03-08 (주)팬바이오넷 Ｃ형 간염바이러스(ｈｃｖ)의 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 탐지방법
WO2004005524A1 (en) * 2002-07-02 2004-01-15 Merck & Co., Inc. Hepatitis c virus particle formation
GB0222824D0 (en) * 2002-10-02 2002-11-06 Moredun Res Inst Bacteriophage-mediated immunisation II
CA3081071A1 (en) * 2002-10-16 2004-04-29 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
AU2003294292A1 (en) * 2002-11-13 2004-06-03 Washington University Highly permissive cell lines for hepatitis c virus replication
EP1694694B1 (en) * 2003-12-01 2013-01-23 Board Of Regents, The University Of Texas System Replication competent hepatitis c virus and methods of use
WO2005054450A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection
ATE491810T1 (de) * 2004-01-23 2011-01-15 Bio Merieux Inc Neuartiges nukleotidgemisch für eine verbesserte nukleinsäurenamplifikationsleistung
AU2005218183B2 (en) 2004-03-02 2012-06-07 Virco Bvba Estimation of clinical cut-offs
WO2005087926A2 (en) 2004-03-05 2005-09-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
US7833987B2 (en) * 2004-03-12 2010-11-16 Indian Institute Of Science Small synthetic RNA, a method of preparing the same and uses thereof
JP5031560B2 (ja) * 2004-06-21 2012-09-19 プロウジェンラ インコーポレーテッド タンパク質分解活性に関連する診断およびスクリーニング方法ならびにキット
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
EP1797112B1 (en) * 2004-09-29 2010-07-21 The Administrators of the Tulane Educational Fund Inhibitors of hepatitits c virus
CN101120086A (zh) * 2005-02-16 2008-02-06 昆士兰医学研究所理事会 用于肿瘤治疗的黄病毒复制子结构
AU2006220887B2 (en) * 2005-03-04 2010-11-04 The Rockefeller University Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof
US20060234348A1 (en) * 2005-04-13 2006-10-19 Bujarski Jozef J Method of production of RNA polymerase protein
JP2007312649A (ja) * 2006-05-24 2007-12-06 Japan Health Science Foundation 再構築された感染性レトロウイルスゲノムクローンｄｎａ及びそれを含む微生物ならびにそれらの製造方法
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US7504255B2 (en) * 2006-08-17 2009-03-17 Saint Louis University Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes
US20080096274A1 (en) * 2006-10-24 2008-04-24 Guangpu Li Recombinant alphavirus vectors and methods of using same
AU2008338803B2 (en) * 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
WO2010050939A1 (en) * 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
US20100129902A1 (en) 2008-11-24 2010-05-27 Erhard Ralf Schoenbrunner Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
JPWO2011024875A1 (ja) * 2009-08-28 2013-01-31 公益財団法人東京都医学総合研究所 Ｃ型肝炎ウイルスの新規株由来のポリヌクレオチド及びその利用
US20110070199A1 (en) * 2009-09-21 2011-03-24 Scheiber Ii Lane Bernard Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases
JP6158171B2 (ja) 2011-05-02 2017-07-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成ｃ型肝炎ゲノム、並びに、その製造方法及びその使用
US20140242669A1 (en) * 2011-08-18 2014-08-28 Ycine Llc Production of infectious rna viruses in yeast
CA2962696A1 (en) 2014-10-01 2016-04-07 National Research Council Of Canada Animal models, cell lines and methods for screening hepatitis c virus vaccines

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5218099A (en) * 1986-04-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Post-transfusion, non-A, non-B hepatitis virus polynucleotides
JP2661044B2 (ja) * 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
US5656731A (en) * 1987-10-15 1997-08-12 Chiron Corporation Nucleic acid-amplified immunoassay probes
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
YU48038B (sh) * 1987-11-18 1996-10-18 Chiron Corp. Postupak za dijagnostiku ne-a, ne-v hepatitisa
HU216017B (hu) * 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
US5312737A (en) * 1988-03-11 1994-05-17 Abbott Laboratories CKS method of HCV protein synthesis
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
US5176994A (en) * 1988-12-21 1993-01-05 Immuno Japan Inc. Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
JP2656995B2 (ja) * 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
DK0414475T3 (da) * 1989-08-25 1998-02-09 Chiron Corp Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
RU2130969C1 (ru) * 1990-04-04 1999-05-27 Чирон Корпорейшн Композиция для диагностики гепатита c человека (варианты), способ и набор для обнаружения антител к вирусу гепатита c человека
DK0527788T3 (da) * 1990-04-04 2004-09-06 Chiron Corp Hepatitis C virus protease
ATE194844T1 (de) * 1990-04-06 2000-08-15 Genelabs Tech Inc Hepatitis c-virus-epitope
ES2069298T3 (es) * 1990-06-30 1995-05-01 Akzo Nobel Nv Secuencias no-a no-b.
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
CA2095521C (en) * 1990-11-08 2009-06-30 Robert O. Ralston Hepatitis c virus asialoglycoproteins
US5654179A (en) * 1990-11-14 1997-08-05 Hri Research, Inc. Nucleic acid preparation methods
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
GB2272443B (en) * 1991-06-10 1995-10-25 Lucky Ltd Nucleotide and amino acid sequences of Korean hepatitis C virus
DE69232871T2 (de) * 1991-06-24 2003-05-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Polypeptide des hepatitis c-virus (hiv)
ES2125268T3 (es) * 1991-07-31 1999-03-01 Hoffmann La Roche Metodos y reactivos para detectar bacterias en liquido cefalorraquideo.
US5428145A (en) * 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
EP0787807B1 (en) * 1991-08-27 2003-05-28 F. Hoffmann-La Roche Ag Primers and probes for hepatitis C detection
EP0532258A2 (en) * 1991-09-09 1993-03-17 Immuno Japan Inc. Oligonucleotides and determination system of HCV genotypes
DE69232859T2 (de) * 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
JPH06105690A (ja) * 1992-03-10 1994-04-19 Kunitada Shimotoono 血液伝播性非ａ非ｂ型肝炎ウィルスｄｎａ
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5552310A (en) * 1992-06-12 1996-09-03 Hiroshi Yoshikura Replication of hepatitis C virus genome and identification of virus having high infectivity
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
JPH06153961A (ja) * 1992-11-27 1994-06-03 Imuno Japan:Kk Ｃ型肝炎ウイルス部分遺伝子、ならびにｃ型肝炎ウイルス遺 伝子の高感度検出法
WO1994020114A1 (en) * 1993-03-12 1994-09-15 Board Of Regents, The University Of Texas System Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs
TW275068B (enExample) * 1993-09-24 1996-05-01 American Cyanamid Co
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof

Also Published As

Publication number Publication date
BR9808147A (pt) 2000-03-28
US20030073080A1 (en) 2003-04-17
JP2008167755A (ja) 2008-07-24
AU742175B2 (en) 2001-12-20
WO1998039031A1 (en) 1998-09-11
JP4223068B2 (ja) 2009-02-12
US20020102540A1 (en) 2002-08-01
CA2283464A1 (en) 1998-09-11
EP1005366A4 (en) 2004-05-19
IL131688A (en) 2007-09-20
IL131688A0 (en) 2001-03-19
JP4094679B2 (ja) 2008-06-04
CA2283464C (en) 2006-09-26
EP1005366A1 (en) 2000-06-07
AU6938698A (en) 1998-09-22
US6392028B1 (en) 2002-05-21
JP2001515353A (ja) 2001-09-18
US6127116A (en) 2000-10-03

Similar Documents

Publication Publication Date Title
ZA981838B (en) Functional DNA clone for hepatitis C virus (HCV) and uses thereof
DE69940817D1 (en) Hepatitis c tripeptide inhibitoren
DE60014345D1 (en) Makrozyklische peptide als hepatitis c virus ns3 protease inhibitore
PL324906A1 (en) Vaccines against viral hepatitis of c type
AU2550995A (en) Hepatitis c virus asialoglycoproteins
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
PL321966A1 (en) Vaccine against viral hepatitis of b type
ZA9811316B (en) Novel hepatitis C virus NS5B protein
EP0973924A4 (en) RECOMBINANT CHIMERAL VIRUSES AND THEIR USE
AU3714499A (en) Hepatitis c virus mimotopes
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
IL143798A0 (en) Hepatitis c virus ns3 protease
EP0747482A3 (en) Recombinant hepatitis GB virus proteins their uses
EP1113777A4 (en) NOVEL HEPATITIS C VIRUS PEPTIDES AND USES THEREOF
IL138804A0 (en) Hepatitis c virus ns5b nucleic acids and proteins
HUP0003511A3 (en) Hepatitis b virus polypeptides
IL116118A0 (en) Papaya ringspot virus coat protein gene
ZA964446B (en) Oligonucleotides specific for hepatitis c virus
HUP0101652A3 (en) Hepatitis vaccine
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
EP1521849A4 (en) HEPATITIS A-VIRUS NUCLEOTIDE SEQUENCES, RECOMBINANT PROTEINS AND THEIR USE
HK1028955A (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
IL137458A0 (en) Genetic immunization with nonstructural proteins of hepatitis c virus